Prithviraj Bose, MD:We have a 58-year-old woman at The University of Texas MD Anderson Cancer Center presenting with some abdominal pain, dizziness, and headaches; blood pressure is a little elevated, just mildly; a slightly enlarged spleen. She’s never had a clot. Hemoglobin count is elevated at 17.1 g/dL. The white blood cell count is elevated as well, 13.2. The EPO [erythropoietin] level is conspicuously low. Bone marrow shows erythroid hyperplasia, and she has aJAK2mutation.
So here we have a lady who pretty clearly has PV [polycythemia vera]. You see that her hemoglobin count is higher than the WHO [World Health Organization] thresholds. She has a low EPO level. She has aJAK2V617Fmutation. She has a bone marrow that’s typical with the erythroid hyperplasia. She has pancytosis with her white blood cell count being elevated as well, so it’s a pretty clear-cut case of PV.
Transcript edited for clarity.
Case: 58-Year-Old Woman Diagnosed With Polycythemia Vera
November 2018
Degree of Anemia Influences Therapy for Myelofibrosis
January 23rd 2025During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Ropeginterferon Alfa-2b Succeeds in Phase 3 Essential Thrombocythemia Trial
January 6th 2025The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.
Read More